Recovery & Tissue Repair · Reviewed by Ian K. Tseng, MD

What Is BPC-157? And Why It Cannot Be Legally Compounded

BPC-157 is one of the most searched compounds in the peptide space and one of the most widely sold online. It is also, as of the FDA's 2023 determination, a substance that cannot be legally compounded in the United States. Both of those things are true simultaneously, and the gap between them is worth understanding before you buy anything.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Plain unlabeled laboratory vial on a bare clinical surface, representing a compound Soothe IV does not offer

Not offered by Soothe IV

This compound cannot be legally prepared by a compounding pharmacy under current FDA restrictions. We do not prescribe or dispense it. This article is here because the question deserves a straight answer, not because we are selling anything.

The short answer

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — derived from a partial sequence identified in human gastric juice. It has been studied primarily in animal models for effects on tendon, ligament, muscle, and gastrointestinal tissue healing. In 2023 the FDA placed it in Category 2 of the 503A Bulks List, the designation for substances presenting significant safety risks, which means compounding pharmacies cannot legally prepare it. Soothe IV does not offer it.

What the compound is

BPC stands for "Body Protection Compound." The peptide is a synthetic fifteen-amino-acid sequence corresponding to a portion of a protein identified in human gastric juice. The original research interest came from the observation that the gastrointestinal tract maintains a remarkable capacity for self-repair in a chemically hostile environment, and the question of what mediates that.

Proposed mechanisms in the literature include effects on angiogenesis — the formation of new blood vessels — modulation of growth factor expression, and interaction with nitric oxide signaling pathways. These are plausible and interesting mechanisms.

What the evidence actually consists of

This is where careful reading matters. The substantial majority of published BPC-157 research is preclinical: rodent models, isolated tissue preparations, and in vitro work. The findings in those models are frequently striking, which is a large part of why the compound developed the reputation it has.

Well-controlled human clinical trials establishing efficacy and safety for the uses discussed online are, at the time of writing, largely absent. That is not a claim that the compound does nothing. It is a statement about the state of the evidence: animal data is a reason to investigate further, not a substitute for human trials. Many compounds with impressive rodent results have not replicated in humans.

Anyone presenting BPC-157 as an established, evidence-backed therapy for human tissue repair is describing a body of research that does not currently exist in that form.

The FDA determination and what it means

In 2023 the FDA reviewed BPC-157 as part of its evaluation of bulk drug substances nominated for use in compounding under section 503A. It placed the substance in Category 2 — substances that raise significant safety risks.

The practical effect is direct: a compounding pharmacy in the United States cannot legally prepare BPC-157 for a patient, and a physician cannot legally have it dispensed against a prescription. This is not a matter of our clinical preference or our risk tolerance. It is the current regulatory status.

The FDA cited limited safety data, uncertainty regarding immunogenicity, and insufficient characterization of the substance among the considerations. Whether this designation changes in the future is genuinely uncertain and is being actively discussed; we monitor it, and if the status changes, we will reassess.

So what are the vendors selling?

BPC-157 remains easy to buy online. Those sellers operate outside the prescription framework by labeling the product "for research use only" or "not for human consumption." That labeling is what permits the sale — it is a legal position, not a disclaimer nobody means.

What you receive is a vial with no prescription, no physician evaluation, no verified purity standard for human administration, no dosing guidance grounded in human data, and no one accountable if you have an adverse reaction. A Certificate of Analysis confirms the contents of the bottle. It does not evaluate whether your body should receive them.

We wrote about this distinction at length in are peptides safe? — it is the single clearest line between a medical program and a research-chemical purchase.

Where this leaves recovery goals

If tissue recovery is what brought you here, the honest answer is that the compound with the most online enthusiasm is currently unavailable through any legitimate channel, and the compounds that are available should be evaluated on their own evidence rather than as substitutes.

What is appropriate for you — if anything — is determined by a physician after evaluation and bloodwork. Not everyone qualifies for therapy, and for some goals the right clinical answer is a non-peptide approach entirely. That is a conversation worth having with someone who has no incentive to sell you a vial.

Frequently asked questions

Is BPC-157 legal?

BPC-157 cannot be legally compounded in the United States. In 2023 the FDA placed it in Category 2 of the 503A Bulks List — the designation for substances presenting significant safety risks — which means compounding pharmacies cannot legally prepare it and physicians cannot have it dispensed against a prescription.

Why does Soothe IV not offer BPC-157?

Because it cannot be legally dispensed by a licensed compounding pharmacy under the current FDA determination. Our program is built on a licensed physician, a Good Faith Examination, bloodwork, and a licensed 503A pharmacy. There is no compliant path to prescribing BPC-157 at present. If the regulatory status changes, we will reassess.

What does the BPC-157 research actually show?

The substantial majority of published research is preclinical — rodent models, isolated tissue preparations, and in vitro work — examining effects on tendon, ligament, muscle, and gastrointestinal healing, with proposed mechanisms involving angiogenesis and growth factor expression. Well-controlled human clinical trials establishing efficacy and safety for the uses discussed online are largely absent. Animal data is a reason to investigate further, not a substitute for human trials.

Vendors sell BPC-157 online. How?

They label it "for research use only" or "not for human consumption," which is the legal position that permits the sale outside the prescription framework. What you receive has no prescription, no physician evaluation, no verified purity standard for human administration, no dosing guidance grounded in human data, and no accountability for adverse reactions. A Certificate of Analysis describes the contents of the vial; it does not assess whether your body should receive them.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator Stable Gastric Pentadecapeptide BPC 157. Current Pharmaceutical Design. 2018. pubmed.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. www.fda.gov
U.S. Food & Drug Administration. Compounding and the FDA: Questions and Answers. www.fda.gov

Ready to talk to a physician?

Start your $50 Application. A physician reviews your goals and labs and tells you what — if anything — fits your situation, including when the answer is that peptide therapy is not the right approach. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.